Clinical start-up of CRS Eglin Pharmaceutical Oral Candidate Drug Phase 1 for new coronavirus

CRS is a complex inflammatory reaction in which a variety of cytokines such as TNF-α, IL-1, IL-6, IL-12, IFN-α, IFN-β, IFN-γ, MCP-1, and IL-8 are produced when CRS occurs.
studies have shown that CRS can cause acute respiratory distress syndrome and multiple organ failure, and is one of the leading causes of death from moderate/severe neocoopedic pneumonia.
addition, many new coronary patients will be discharged from the hospital after a second cytokine storm.
the oral drug EG-009, which the company is developing, inhibits the activity of multiple cytokines to achieve the effects of treating moderate/severe neocyclind pneumonia and reducing patient mortality, according to Eglin Pharmaceuticals press release.
phase 1 clinical trial of the drug was approved by the FDA in September.
addition to this oral preparation candidate, Eglin Pharma is also planning to develop another phase 2 clinical phase of the new crown drug, EG-009A Injection, in the field of new crown therapy research and development.
is understood that the clinical trial's IND and clinical options have been approved by the FDA and will be developed for use in severe patients who need to use a ventilator immediately after hospitalization.
: s1. Eglin Pharma Press Release s. Eglin Pharma.Source:Supplied